Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that CD20 + status confers therapeutic sensitivity to Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vincristine in patients with Non-Hodgkin Lymphoma.
The Republic of Ireland's Health Service Executive (HSE) has approved rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisolone (21 days) for reimbursement as a treatment option for the treatemnt of patients with CD20 positive non-Hodgkin's lymphoma. This indication is also generally for cyclophosphamide, doxorubicin, vincristine, and prednisolone as a treatment option for patients non-Hodgkin's lymphoma, and the treatment regimen notes that rituximab should be included for CD20+ patients.
This statement is based on a regulatory approval from the Health Service Executive:
Treatment of Non Hodgkins Lymphoma (NHL). Rituximab to be included in CD20 positive patients.